CoChat

Efficacy and safety evaluation of HSD‐1 inhibitor ABT‐384 in Alzheimer's disease

Marek, Gerard J., Katz, David A., Meier, Andreas, Greco, Nicholas, Zhang, Wuyan, Liu, Wei, Lenz, Robert A. · 2014 · Alzheimer's & Dementia
Cited by 42

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: In this study we assessed increased cortisol in Alzheimer's disease (AD) patients. The selective 11‐β‐hydroxysteroid dehydrogenase type 1 (HSD‐1) inhibitor ABT‐384 blocked regeneration of active cortisol and this tests the hypothesis that intracellular hypercortisolism contributes to cognitive impairment. Methods: In this double‐blind, placebo‐ and active‐controlled phase II study we examine the efficacy and safety of ABT‐384 given 10 mg or 50 mg once daily, donepezil 10 mg once daily, or placebo for 12 weeks in subjects with mild‐to‐moderate AD. The primary efficacy end point was the change from baseline to final evaluation on the 13‐item Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS‐Cog) total score. Results: The study was terminated for futility after randomization of 267 subjects. ABT‐384 did not improve ADAS‐Cog scores or any secondary end point; however, donepezil significantly improved both cognition and functional end points. Overall incidence of adverse events was similar among treatment groups. Conclusion: ABT‐384, when tested at doses associated with complete brain HSD‐1 inhibition, did not produce symptomatic improvement in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.09.010

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 42

Metadata

Authors
Marek, G. J., Katz, D. A., Meier, A., Greco, N., Zhang, W., Liu, W., & Lenz, R. A.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-01-13
Volume
10
Issue
5S
Pages
S364-73
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2130325529
Cited by
42
References
10
FWCI
2.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety evaluation of HSD‐1 inhibitor ABT‐384 in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2013.09.010
The paper
Marek, G. J., Katz, D. A., Meier, A., Greco, N., Zhang, W., Liu, W., & Lenz, R. A. (2014). Efficacy and safety evaluation of HSD‐1 inhibitor ABT‐384 in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2013.09.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.